Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime? Response by Hanrahan, E, Ryan, A, Heymach, J

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC by Heymach, J, Hanrahan, E, Mann, H, Langmuir, P, Natale, R, Johnson, B, Herbst, R, Ryan, A

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. by Hanrahan, E, Ryan, A, Mann, H, Kennedy, S, Langmuir, P, Natale, R, Herbst, R, Johnson, B, Heymach, J

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. by Hanrahan, E, Lin, H, Kim, E, Yan, S, Du, D, McKee, K, Tran, H, Lee, J, Ryan, A, Langmuir, P, Johnson, B, Heymach, J